A little over a year ago, I wrote an article expressing my opinion about the drug donanemab; at that time it was being promoted as a “BREAKTHROUGH” in Alzheimer’s research, but the scientific data did not support such expectations. Today, Lecanemab (Leqembi) has been approved by the European Commission to treat early‑stage Alzheimer’s disease. However, … Continue reading Lecanemab and Beyond: Shifting from Pharma Hype to Real Neuroprotective Care
Tag: blog
Depresión: La Epidemia del Siglo XXI
Antes de profundizar en este tema, es crucial considerar algunos datos clave: La depresión mayor es el trastorno neuropsiquiátrico más prevalente en nuestra sociedad y, a su vez, una de las principales causas de ausentismo laboral en el mundo. Su impacto trasciende el ámbito individual, afectando no solo la calidad de vida de quienes la … Continue reading Depresión: La Epidemia del Siglo XXI
The Impact of Neuroprotection on Long-Term Mental Health During Global Crises.
When we talk about neuroprotection, it's natural to think of it in relation to conditions or treatments that impact human health, particularly mental well-being. However, what happens when the mental health of the world itself is at risk? Global crises, environmental stressors, and societal challenges can severely affect our collective cognitive resilience, that's why considering … Continue reading The Impact of Neuroprotection on Long-Term Mental Health During Global Crises.
Dr. Jonathan A. Cortés Silva 